Invest Today

Why now?

  • Strategic distribution launch imminent (200+ sales reps and clinical staff via a national MedTech partner)

  • 30 hospitals successfully onboarded, with a target of 50 by year-end

  • Reflow Mini is currently reimbursed; while also pursuing additional FDA claims and NTAP reimbursement

  • Expanding Pipeline:

    • ReFlow Mini: FDA Cleared, breakthrough designation and commercially available

    • ReFlow EVD: Breakthrough designation, TAP - Expected 2026

    • ReFlow RMS: Remote Brain Monitoring - Targeted 2027

Capital and Exit

Series A $4M

  • A-1 Preferred Stock at $.2819/share

  • 6% cumulative annual dividend

  • Presently closed $2.6M

  • Soft-circled commitments of $1M

  • Pre-Money Valuation: $22M

  • Requesting Commitments by 6/15/25

  • Final Close 7/15/25

Series B $10M

  • Funds EVD Launch and RMS Development

  • Targets strategic exit by 2028

Backed By Experienced Investors